{"id":"vfend-voriconazole","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It achieves this by targeting the enzyme lanosterol 14α-demethylase, which is necessary for the conversion of lanosterol to ergosterol. This disruption of ergosterol synthesis ultimately leads to the death of fungal cells. Voriconazole has a broad spectrum of activity, making it effective against a wide range of fungal pathogens.","oneSentence":"Voriconazole is an antifungal medication that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:33.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of invasive aspergillosis, candidemia, and other serious fungal infections"}]},"trialDetails":[{"nctId":"NCT00353158","phase":"PHASE1","title":"A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2007-05-25","conditions":"Healthy Volunteers, Fungal Infections, Bacterial Infections","enrollment":62},{"nctId":"NCT04988555","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-02-28","conditions":"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma","enrollment":606},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07457203","phase":"PHASE1","title":"Study on the Drug Interaction Between Buagafuran and Voriconazole","status":"NOT_YET_RECRUITING","sponsor":"Beijing Union Pharmaceutical Factory Ltd","startDate":"2026-04","conditions":"Drug Drug Interaction (DDI)","enrollment":18},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07426042","phase":"PHASE1","title":"Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects","status":"NOT_YET_RECRUITING","sponsor":"Min Kyu Park","startDate":"2026-04","conditions":"Drug-Drug Interactions","enrollment":12},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT07362693","phase":"","title":"A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-12-31","conditions":"ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)","enrollment":50},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT04868188","phase":"","title":"Pharmacokinetics of Voriconazole in Adult ECMO Patients","status":"COMPLETED","sponsor":"University Hospitals, Leicester","startDate":"2021-08-10","conditions":"Aspergillosis, Influenza, Covid19","enrollment":32},{"nctId":"NCT07320235","phase":"PHASE1","title":"Imetelstat Combinations in Relapsed AML","status":"RECRUITING","sponsor":"Douglas Tremblay","startDate":"2026-01","conditions":"Relapsed Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT05822544","phase":"PHASE1","title":"Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes","status":"RECRUITING","sponsor":"OrsoBio, Inc","startDate":"2023-04-22","conditions":"Healthy Subjects, Obesity, Type 2 Diabetes","enrollment":564},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07244367","phase":"NA","title":"Maintenance Venetoclax in AML Fit Patients","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-09-01","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":80},{"nctId":"NCT06510699","phase":"PHASE2","title":"Pharmacogenomics for Better Treatment of Fungal Infections in Cancer","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2025-04-14","conditions":"Fungal Infection, Haematological Malignancy, Blood Cancer","enrollment":104},{"nctId":"NCT06774144","phase":"PHASE3","title":"Rezafungin Prophylaxis in Liver Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2025-10-15","conditions":"Liver Transplant Infection, Fungal Infection","enrollment":385},{"nctId":"NCT02731638","phase":"PHASE3","title":"Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-09","conditions":"Corneal Ulcer, Fungal Keratitis","enrollment":70},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06493409","phase":"PHASE1","title":"A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-26","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07101497","phase":"PHASE2","title":"Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-08-01","conditions":"Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy","enrollment":60},{"nctId":"NCT07084584","phase":"PHASE1, PHASE2","title":"An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Galecto Biotech AB","startDate":"2026-06-10","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":184},{"nctId":"NCT07072923","phase":"PHASE4","title":"Antibiotic Impregnated Beads in Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2025-09-01","conditions":"Osteomyelitis of the Foot, Antibiotic Impregnated Beads, Osteomyelitis of Lower Extremities","enrollment":100},{"nctId":"NCT04865419","phase":"PHASE1","title":"Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-06-11","conditions":"Haematological Malignancies","enrollment":46},{"nctId":"NCT00238355","phase":"PHASE2","title":"Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2003-08","conditions":"Infection, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":13},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":"HIV/AIDS-associated Talaromycosis","enrollment":116},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT00413218","phase":"PHASE3","title":"Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03-08","conditions":"Candidiasis, Invasive, Candidemia, Mycoses","enrollment":450},{"nctId":"NCT00412893","phase":"PHASE3","title":"Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03-07","conditions":"Aspergillosis, Invasive Fungal Infection","enrollment":527},{"nctId":"NCT05458102","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-08-19","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":18},{"nctId":"NCT02014558","phase":"PHASE1, PHASE2","title":"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-10-09","conditions":"Acute Myeloid Leukemia","enrollment":265},{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":"Phototoxicity","enrollment":12},{"nctId":"NCT05897294","phase":"","title":"Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis","status":"NO_LONGER_AVAILABLE","sponsor":"TFF Pharmaceuticals, Inc.","startDate":"","conditions":"Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis","enrollment":""},{"nctId":"NCT06680544","phase":"PHASE2","title":"Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2024-11-15","conditions":"Dermatophyte Infection","enrollment":120},{"nctId":"NCT04551963","phase":"PHASE1","title":"Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-11-15","conditions":"B-cell Malignancies","enrollment":26},{"nctId":"NCT01686607","phase":"","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-01","conditions":"Systemic Fungal Infections","enrollment":40110},{"nctId":"NCT03066011","phase":"","title":"Registry of Patients Treated With Systemic Mold-Active Triazoles","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-03-16","conditions":"Invasive Fungal Infection","enrollment":2015},{"nctId":"NCT01503515","phase":"PHASE3","title":"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-03-21","conditions":"Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":292},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":"Bacterial Vaginosis","enrollment":200},{"nctId":"NCT06582186","phase":"PHASE4","title":"Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2024-10","conditions":"Aspergillosis Invasive, Fungal Infection, Hematologic Malignancy","enrollment":30},{"nctId":"NCT04824417","phase":"PHASE3","title":"A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-03-01","conditions":"Chronic Pulmonary Aspergillosis","enrollment":116},{"nctId":"NCT03672292","phase":"PHASE2","title":"Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2019-01-22","conditions":"Invasive Pulmonary Aspergillosis","enrollment":22},{"nctId":"NCT05841771","phase":"PHASE2","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-01-01","conditions":"Hypomethylating Agent, Venetoclax, Myeloid Malignancy","enrollment":78},{"nctId":"NCT06392529","phase":"","title":"Efficacy of Voriconazole Loaded Spanlastics Gel Versus Clotriamazole Cream on Treating Vulvovaginal Candidasis","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-05-10","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT04876716","phase":"PHASE3","title":"Azole-echinocandin Combination Therapy for Invasive Aspergillosis","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2021-05-11","conditions":"Invasive Aspergillosis","enrollment":66},{"nctId":"NCT06137690","phase":"","title":"Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients","status":"UNKNOWN","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-07-01","conditions":"Invasive Fungal Infection","enrollment":550},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT01782131","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-25","conditions":"Fungal Infections, Invasive Pulmonary Aspergillosis","enrollment":585},{"nctId":"NCT05918198","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-02-01","conditions":"Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT05708625","phase":"PHASE3","title":"Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-01-01","conditions":"Leishmaniasis, Cutaneous","enrollment":136},{"nctId":"NCT01576315","phase":"PHASE2","title":"ATCF (Azole Therapy in Cystic Fibrosis)","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2014-06","conditions":"Cystic Fibrosis, Aspergillus Infections","enrollment":11},{"nctId":"NCT02674685","phase":"","title":"Vfend Special Investigation For Prophylaxis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-03-11","conditions":"Fungal Infection","enrollment":241},{"nctId":"NCT00075803","phase":"PHASE3","title":"Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2003-11","conditions":"Lymphoma, Infection, Leukemia","enrollment":600},{"nctId":"NCT05264142","phase":"PHASE1","title":"Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2022-04-01","conditions":"Healthy","enrollment":45},{"nctId":"NCT05528354","phase":"EARLY_PHASE1","title":"Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-06-02","conditions":"Hematopoietic Stem Cell Transplantation, TP53","enrollment":58},{"nctId":"NCT05456048","phase":"","title":"Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-12-03","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality","enrollment":231},{"nctId":"NCT05380245","phase":"PHASE4","title":"Drug-Drug Interaction Study of Voriconazole With Clarithromycin.","status":"COMPLETED","sponsor":"Abdul Wali Khan University Mardan","startDate":"2018-11-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT02329808","phase":"","title":"Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-06","conditions":"Hematologic Diseases, Oncology Problem, Kidney Diseases","enrollment":93},{"nctId":"NCT04004078","phase":"","title":"An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM","status":"COMPLETED","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-03-01","conditions":"Invasive Fungal Infection","enrollment":314},{"nctId":"NCT05330000","phase":"PHASE1","title":"Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-05-22","conditions":"Healthy Adults","enrollment":48},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT03121235","phase":"","title":"PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2017-04-20","conditions":"Aspergillosis, Invasive Pulmonary","enrollment":320},{"nctId":"NCT05268718","phase":"EARLY_PHASE1","title":"Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08-01","conditions":"Keratitis, Ulcerative, Antibiotic Resistance, Microbial, Photothermal Therapy","enrollment":20},{"nctId":"NCT00745992","phase":"","title":"Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-10","conditions":"Invasive Fungal Infections","enrollment":200},{"nctId":"NCT01869829","phase":"","title":"PEACE: Pediatric Antifungal Comparative Effectiveness","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Pediatric Invasive Candidiasis","enrollment":750},{"nctId":"NCT04576325","phase":"PHASE1","title":"Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"TFF Pharmaceuticals, Inc.","startDate":"2020-11-15","conditions":"Asthma","enrollment":17},{"nctId":"NCT04229303","phase":"PHASE1","title":"Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2020-02-11","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":58},{"nctId":"NCT04966234","phase":"PHASE2, PHASE3","title":"A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-04-22","conditions":"Cystic Fibrosis, Aspergillosis","enrollment":135},{"nctId":"NCT03471988","phase":"PHASE3","title":"Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2018-04-16","conditions":"Deep Mycosis","enrollment":103},{"nctId":"NCT04872231","phase":"PHASE1","title":"Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects","status":"COMPLETED","sponsor":"TFF Pharmaceuticals, Inc.","startDate":"2019-11-22","conditions":"Healthy","enrollment":65},{"nctId":"NCT02554656","phase":"","title":"Vfend Special Investigation For Pediatric - Observational","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-10-27","conditions":"Pediatric Safety and Effectiveness","enrollment":89},{"nctId":"NCT01950507","phase":"PHASE1","title":"Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02-20","conditions":"Stem Cell Transplantation, Graft vs Host Disease","enrollment":15},{"nctId":"NCT04743544","phase":"","title":"Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy","status":"UNKNOWN","sponsor":"Dokuz Eylul University","startDate":"2019-11-01","conditions":"Adverse Drug Reactions","enrollment":62},{"nctId":"NCT04072640","phase":"EARLY_PHASE1","title":"Three Induction Treatments on Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-01-25","conditions":"Cryptococcal Meningitis, HIV/AIDS","enrollment":120},{"nctId":"NCT02180165","phase":"PHASE3","title":"Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-07-29","conditions":"Aspergillosis","enrollment":116},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT04145583","phase":"PHASE1","title":"A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2019-12-14","conditions":"Anesthesia, Sedation","enrollment":16},{"nctId":"NCT03731169","phase":"PHASE4","title":"CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-01-10","conditions":"Aspergillosis Invasive, Fungal Infection","enrollment":30},{"nctId":"NCT02283905","phase":"PHASE4","title":"Amphotericin-B and Voriconazole for Pulmonary Blastomycosis","status":"TERMINATED","sponsor":"University of Manitoba","startDate":"2015-06","conditions":"Blastomycosis","enrollment":2},{"nctId":"NCT04552353","phase":"PHASE4","title":"Evaluate Bioequivalence of Voriconazole(200mg/Vial) .","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2020-06-13","conditions":"Antimycotic for Systematic Use","enrollment":14},{"nctId":"NCT04547335","phase":"","title":"The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole","status":"UNKNOWN","sponsor":"Dokuz Eylul University","startDate":"2019-11-01","conditions":"Adverse Drug Reactions","enrollment":34},{"nctId":"NCT04502771","phase":"","title":"Therapeutic Drug Monitoring of Antifungals in Intensive Care Units","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-01-01","conditions":"Intensive Care Unit Patients","enrollment":200},{"nctId":"NCT04502355","phase":"","title":"Voriconazole-Induced QT Interval Prolongation: A Prospective Study","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2016-10-31","conditions":"Voriconazole Induced QT Interval Prolongation","enrollment":60},{"nctId":"NCT00079222","phase":"NA","title":"Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-11","conditions":"Cancer","enrollment":""},{"nctId":"NCT02904434","phase":"","title":"Gastrointestinal Implications of Voriconazole Exposure","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2016-09","conditions":"Infection","enrollment":""},{"nctId":"NCT02631954","phase":"PHASE1","title":"Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-09","conditions":"Aspergillus Infections, Candida Infections, Fungal Infections","enrollment":24},{"nctId":"NCT03787550","phase":"","title":"PK/PD of the Sedatives, Analgesics and Antibiotics in Patients Receiving ECMO","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-02-07","conditions":"Drug Effect","enrollment":36},{"nctId":"NCT04238884","phase":"PHASE4","title":"Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-01-02","conditions":"Invasive Fungal Infections","enrollment":146},{"nctId":"NCT04225195","phase":"PHASE2","title":"Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01","conditions":"Invasive Candidiasis, Invasive Aspergillosis","enrollment":60},{"nctId":"NCT04110860","phase":"PHASE2","title":"Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel","status":"COMPLETED","sponsor":"Sara Botros","startDate":"2018-02-15","conditions":"Tinea Versicolor","enrollment":30},{"nctId":"NCT02576366","phase":"PHASE4","title":"Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-06","conditions":"Drug Interactions, Kidney Transplantation","enrollment":24},{"nctId":"NCT02227797","phase":"PHASE1","title":"MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-19","conditions":"Fungal Infection","enrollment":66},{"nctId":"NCT03327727","phase":"PHASE2","title":"VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults","status":"TERMINATED","sponsor":"Vical","startDate":"2018-02-20","conditions":"Invasive Aspergillosis, Invasive Pulmonary Aspergillosis","enrollment":4},{"nctId":"NCT00997035","phase":"PHASE3","title":"The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-05","conditions":"Corneal Ulcer, Eye Infections, Fungal","enrollment":240},{"nctId":"NCT03067350","phase":"","title":"Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2015-01","conditions":"Invasive Aspergillosis, Haematological Cancer Patients, Voriconazole","enrollment":47},{"nctId":"NCT03827278","phase":"NA","title":"Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2018-12-30","conditions":"Talaromyces in Human Immunodeficiency Virus Negative, To Compare Voriconazole and Amphotericin Sequential Itraconazole Therapy, To Dynamically Monitor the Anti-Interferon-γ Autoantibodies","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vfend"],"phase":"phase_3","status":"active","brandName":"Vfend - voriconazole","genericName":"Vfend - voriconazole","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole, also known as Vfend, is a small molecule inhibitor that targets the cytochrome P450 51 enzyme, specifically inhibiting lanosterol 14-alpha demethylase. It is used to treat various conditions, including coronavirus infection (COVID-19), according to ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}